Mirtazapine is a tetracyclic piperazino-azepine antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder. The effects of this drug may be observed as early ...
This drug is indicated for the treatment of major depressive disorder and its associated symptoms.
...
SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
Beijing Anding Hospital, Beijing, Beijing, China
Riley Child and Adolescent Psychiatry Clinic Riley Hospital, Indianapolis, Indiana, United States
Lurie Center -MassGeneral Hospital, Lexington, Massachusetts, United States
Beijing Anding Hospital, Capital Medical University, Beijing, Beijing, China
University Hospitals, Leuven, Vlaanderen, Belgium
Anxiety Disorders Clinic, New York State Psychiatric Institute, New York, New York, United States
Dartmouth Medical School Department of Psychiatry's Addition Research Center, Bedford, New Hampshire, United States
Dartmouth Medical School Department of Psychiatry's Addiction Research Center, Hanover, New Hampshire, United States
Nagoya City University Hospital, Nagoya, Aichi, Japan
Kochi Medical School Hospital, Nangoku, Kochi, Japan
Samsung Medical Center, Kangnam, Seoul, Korea, Republic of
Cl Sn Nicol, San Nicolas, Bs As, Argentina
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.